



## Clinical trial results:

### A Randomized, Double-blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 798 Compared with Rituximab in Subjects with CD20 Positive B-cell Non-Hodgkin Lymphoma (NHL)

#### Summary

|                          |                            |
|--------------------------|----------------------------|
| EudraCT number           | 2013-005542-11             |
| Trial protocol           | DE CZ RO IT ES FR BG PL GR |
| Global end of trial date | 28 June 2019               |

#### Results information

|                                |              |
|--------------------------------|--------------|
| Result version number          | v1 (current) |
| This version publication date  | 12 July 2020 |
| First version publication date | 12 July 2020 |

#### Trial information

##### Trial identification

|                       |          |
|-----------------------|----------|
| Sponsor protocol code | 20130109 |
|-----------------------|----------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT02747043 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |                                                                                       |
|------------------------------|---------------------------------------------------------------------------------------|
| Sponsor organisation name    | Amgen Inc.                                                                            |
| Sponsor organisation address | One Amgen Center Drive, Thousand Oaks, United States, 91320                           |
| Public contact               | IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com |
| Scientific contact           | IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com |

Notes:

#### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |              |
|------------------------------------------------------|--------------|
| Analysis stage                                       | Final        |
| Date of interim/final analysis                       | 28 June 2019 |
| Is this the analysis of the primary completion data? | No           |
| Global end of trial reached?                         | Yes          |
| Global end of trial date                             | 28 June 2019 |
| Was the trial ended prematurely?                     | No           |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective for this study was to evaluate the efficacy of ABP 798 compared with rituximab.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) regulations and guidelines, and Food and Drug Administration (FDA) regulations, and guidelines set forth in 21 CFR Parts 11, 50, 54, 56, and 312.

All subjects provided written informed consent before undergoing any study-related procedures, including screening procedures.

The study protocol, amendments, and the informed consent form (ICF) were reviewed by the Institutional Review Boards (IRBs) and Independent Ethics Committees (IECs). No subjects were recruited into the study and no investigational product (IP) was shipped until the IRB/IEC gave written approval of the protocol and ICF and Amgen received copies of these approvals.

Background therapy: -

Evidence for comparator: -

|                                                           |             |
|-----------------------------------------------------------|-------------|
| Actual start date of recruitment                          | 25 May 2016 |
| Long term follow-up planned                               | No          |
| Independent data monitoring committee (IDMC) involvement? | Yes         |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                        |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Italy: 50              |
| Country: Number of subjects enrolled | Spain: 33              |
| Country: Number of subjects enrolled | France: 24             |
| Country: Number of subjects enrolled | Germany: 15            |
| Country: Number of subjects enrolled | Ukraine: 12            |
| Country: Number of subjects enrolled | Czech Republic: 11     |
| Country: Number of subjects enrolled | Georgia: 9             |
| Country: Number of subjects enrolled | Greece: 8              |
| Country: Number of subjects enrolled | Poland: 4              |
| Country: Number of subjects enrolled | Bulgaria: 3            |
| Country: Number of subjects enrolled | Romania: 3             |
| Country: Number of subjects enrolled | Israel: 2              |
| Country: Number of subjects enrolled | India: 16              |
| Country: Number of subjects enrolled | Korea, Republic of: 16 |
| Country: Number of subjects enrolled | Australia: 14          |
| Country: Number of subjects enrolled | Canada: 7              |

|                                      |                  |
|--------------------------------------|------------------|
| Country: Number of subjects enrolled | United States: 7 |
| Country: Number of subjects enrolled | Mexico: 4        |
| Country: Number of subjects enrolled | Colombia: 3      |
| Country: Number of subjects enrolled | Japan: 15        |
| Worldwide total number of subjects   | 256              |
| EEA total number of subjects         | 151              |

Notes:

---

### Subjects enrolled per age group

|                                           |     |
|-------------------------------------------|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 169 |
| From 65 to 84 years                       | 87  |
| 85 years and over                         | 0   |

## Subject disposition

### Recruitment

Recruitment details:

A total of 380 subjects were screened and 256 participants (128 in the ABP 798 treatment group and 128 in the rituximab treatment group) were randomized at 91 centers across 20 countries.

### Pre-assignment

Screening details:

Participants were randomized centrally to receive either ABP 798 or rituximab in a 1:1 manner. The randomization was stratified based on geographic region (Europe, Americas, Japan, Asia Pacific – Other) and age group ( $> 60$  years of age,  $\leq 60$  years of age).

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Double blind                   |
| Roles blinded                | Subject, Investigator, Monitor |

Blinding implementation details:

Since the investigational product containers were different for ABP 798 and rituximab, investigational product (ABP 798 or rituximab) was prepared by an unblinded pharmacist or designee, into a common IV preparation, for administration to the subject.

### Arms

|                              |         |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes     |
| <b>Arm title</b>             | ABP 798 |

Arm description:

ABP 798 was administered at a dose of  $375 \text{ mg/m}^2$  as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.

|                                        |                                       |
|----------------------------------------|---------------------------------------|
| Arm type                               | Experimental                          |
| Investigational medicinal product name | ABP 798                               |
| Investigational medicinal product code |                                       |
| Other name                             | biosimilar to Rituximab               |
| Pharmaceutical forms                   | Concentrate for solution for infusion |
| Routes of administration               | Intravenous use                       |

Dosage and administration details:

ABP 798 was supplied as a sterile, preservative-free liquid concentrate for IV infusion at a concentration of  $10 \text{ mg/mL}$  in either  $100 \text{ mg}/10 \text{ mL}$  or  $500 \text{ mg}/50 \text{ mL}$  single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.

|                  |           |
|------------------|-----------|
| <b>Arm title</b> | Rituximab |
|------------------|-----------|

Arm description:

Rituximab was administered at a dose of  $375 \text{ mg/m}^2$  as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.

|                                        |                                       |
|----------------------------------------|---------------------------------------|
| Arm type                               | Active comparator                     |
| Investigational medicinal product name | Rituximab                             |
| Investigational medicinal product code |                                       |
| Other name                             | Rituxan                               |
| Pharmaceutical forms                   | Concentrate for solution for infusion |
| Routes of administration               | Intravenous use                       |

Dosage and administration details:

Rituximab was procured from commercial supplies in the US and was supplied as a sterile, clear, colorless, preservative-free liquid concentrate for IV infusion at a concentration of  $10 \text{ mg/mL}$  in either  $100\text{-mg}/10 \text{ mL}$  or  $500\text{-mg}/50 \text{ mL}$  single-dose vials. Subjects were to receive premedications before

each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.

| <b>Number of subjects in period 1</b> | ABP 798 | Rituximab |
|---------------------------------------|---------|-----------|
| Started                               | 128     | 128       |
| Treated                               | 128     | 126       |
| Completed                             | 118     | 123       |
| Not completed                         | 10      | 5         |
| Consent withdrawn by subject          | 1       | 1         |
| Physician decision                    | 1       | 1         |
| Disease progression                   | 4       | -         |
| Adverse event, non-fatal              | 3       | 1         |
| not specified                         | 1       | 1         |
| Protocol deviation                    | -       | 1         |

## Baseline characteristics

### Reporting groups

|                                                                                                                                                            |           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Reporting group title                                                                                                                                      | ABP 798   |
| Reporting group description:                                                                                                                               |           |
| ABP 798 was administered at a dose of 375 mg/m <sup>2</sup> as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20. |           |
| Reporting group title                                                                                                                                      | Rituximab |
| Reporting group description:                                                                                                                               |           |
| Rituximab was administered at a dose of 375 mg/m <sup>2</sup> as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.             |           |

| Reporting group values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | ABP 798 | Rituximab | Total |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|-----------|-------|
| Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 128     | 128       | 256   |
| Age Categorical                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |         |           |       |
| Units:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |         |           |       |
| <= 60 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 71      | 70        | 141   |
| > 60 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 57      | 58        | 115   |
| Age Continuous                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |         |           |       |
| Units: years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |         |           |       |
| arithmetic mean                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 57.6    | 58.2      |       |
| standard deviation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | ± 12.72 | ± 12.20   | -     |
| Sex: Female, Male                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |         |           |       |
| Units:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |         |           |       |
| Female                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 68      | 62        | 130   |
| Male                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 60      | 66        | 126   |
| Race/Ethnicity, Customized                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |         |           |       |
| Units: Subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |         |           |       |
| White                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 102     | 101       | 203   |
| Asian, Non-Japanese                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 17      | 14        | 31    |
| Asian, Japanese                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 7       | 8         | 15    |
| Missing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1       | 2         | 3     |
| Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0       | 2         | 2     |
| American Indian or Alaska Native                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 1       | 0         | 1     |
| White, Asian-Non-Japanese                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0       | 1         | 1     |
| Race/Ethnicity, Customized                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |         |           |       |
| Units: Subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |         |           |       |
| Not Hispanic or Latino                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 119     | 119       | 238   |
| Hispanic or Latino                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 8       | 7         | 15    |
| Not allowed to collect                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1       | 2         | 3     |
| Eastern Cooperative Oncology Group (ECOG) Status                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |         |           |       |
| Scale used to assess how a patient's disease is progressing, how the disease affects the daily living abilities of the patient: 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory, able to carry out work of a light nature; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about > 50% of waking hours; 3 = Capable of only limited self care, confined to a bed or chair > 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead. |         |           |       |
| Units: Subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |         |           |       |
| Grade 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 107     | 110       | 217   |
| Grade 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21      | 18        | 39    |

|                                                                                         |                    |                    |     |
|-----------------------------------------------------------------------------------------|--------------------|--------------------|-----|
| Region of Enrollment<br>Units: Subjects                                                 |                    |                    |     |
| Europe                                                                                  | 88                 | 86                 | 174 |
| Asia Pacific - Other                                                                    | 23                 | 23                 | 46  |
| Americas                                                                                | 10                 | 11                 | 21  |
| Japan                                                                                   | 7                  | 8                  | 15  |
| Previous Radiation Treatment<br>Units: Subjects                                         |                    |                    |     |
| Yes                                                                                     | 3                  | 3                  | 6   |
| No                                                                                      | 125                | 125                | 250 |
| Weight<br>Units: kg<br>arithmetic mean<br>standard deviation                            | 75.29<br>± 19.135  | 75.19<br>± 16.981  | -   |
| Height<br>Units: cm<br>arithmetic mean<br>standard deviation                            | 166.81<br>± 10.737 | 167.64<br>± 10.292 | -   |
| Time Since Original Diagnosis<br>Units: months<br>arithmetic mean<br>standard deviation | 6.31<br>± 16.325   | 5.17<br>± 10.181   | -   |

## End points

### End points reporting groups

|                                                                                                                                                                                            |           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Reporting group title                                                                                                                                                                      | ABP 798   |
| Reporting group description:<br>ABP 798 was administered at a dose of 375 mg/m <sup>2</sup> as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20. |           |
| Reporting group title                                                                                                                                                                      | Rituximab |
| Reporting group description:<br>Rituximab was administered at a dose of 375 mg/m <sup>2</sup> as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.             |           |

### Primary: Percentage of Participants Who Responded (Overall Response Rate - ORR) by Week 28 Based on Independent Central Assessment of Disease

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Percentage of Participants Who Responded (Overall Response Rate - ORR) by Week 28 Based on Independent Central Assessment of Disease |
| End point description:<br>Overall response within the first treatment cycle was assessed according to International Working Group – Non-Hodgkin Lymphoma criteria (IWG-NHL criteria [Cheson et al, 1999]) by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement), and bone marrow biopsy (to assess bone marrow infiltration). ORR was the percentage of participants with a best overall response of complete response (CR), unconfirmed complete response (CRu) or partial response (PR). Participants that do not meet the criteria for response were considered non-responders.<br><br>CR was defined as no evidence of disease.<br>CRu showed nodes in the original sum of the products (SPD) regressed by >75% and/or indeterminate bone marrow results.<br>PR was a ≥ 50% decrease in SPD of the six largest dominant nodes; ≥50% decrease in liver and spleen nodes, and no increase in size of other nodes nor any new sites of disease. |                                                                                                                                      |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Primary                                                                                                                              |
| End point timeframe:<br>Post treatment up to Week 28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                      |

| End point values                  | ABP 798            | Rituximab          |  |  |
|-----------------------------------|--------------------|--------------------|--|--|
| Subject group type                | Reporting group    | Reporting group    |  |  |
| Number of subjects analysed       | 123 <sup>[1]</sup> | 124 <sup>[2]</sup> |  |  |
| Units: percentage of participants |                    |                    |  |  |
| number (not applicable)           | 78.0               | 70.2               |  |  |

Notes:

[1] - The modified full analysis set (mFAS) includes subjects with evidence of disease at baseline

[2] - mFAS

### Statistical analyses

|                                                                                                                                                                                                                                                                                                                                             |                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| Statistical analysis title                                                                                                                                                                                                                                                                                                                  | Risk Difference analysis of ORR by Week 28: 90% CI |
| Statistical analysis description:<br>Clinical equivalence of the primary endpoint will first be demonstrated by comparing the 1-sided 95% lower confidence limit of the RD of ORR by week 28 between ABP 798 and rituximab with a noninferiority margin of -15%. If this is successful, the 1-sided upper 95% confidence limit of the RD of |                                                    |

ORR by week 28 will be compared with a nonsuperiority margin of +35.5%.

|                                         |                      |
|-----------------------------------------|----------------------|
| Comparison groups                       | Rituximab v ABP 798  |
| Number of subjects included in analysis | 247                  |
| Analysis specification                  | Pre-specified        |
| Analysis type                           | other                |
| Parameter estimate                      | Risk difference (RD) |
| Point estimate                          | 7.7                  |
| Confidence interval                     |                      |
| level                                   | 90 %                 |
| sides                                   | 2-sided              |
| lower limit                             | -1.4                 |
| upper limit                             | 16.8                 |

---

**Statistical analysis title**

Risk Difference analysis of ORR by Week 28: 95% CI

Statistical analysis description:

2-sided 95% confidence interval will be evaluated against a symmetrical margin of 15% for noninferiority and nonsuperiority

|                                         |                      |
|-----------------------------------------|----------------------|
| Comparison groups                       | ABP 798 v Rituximab  |
| Number of subjects included in analysis | 247                  |
| Analysis specification                  | Pre-specified        |
| Analysis type                           |                      |
| Parameter estimate                      | Risk difference (RD) |
| Point estimate                          | 7.7                  |
| Confidence interval                     |                      |
| level                                   | 95 %                 |
| sides                                   | 2-sided              |
| lower limit                             | -3.2                 |
| upper limit                             | 18.6                 |

---

**Secondary: Percentage of Participants Who Responded (Overall Response Rate - ORR) at Week 12 Based on Independent Central Assessment of Disease**

|                 |                                                                                                                                      |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants Who Responded (Overall Response Rate - ORR) at Week 12 Based on Independent Central Assessment of Disease |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Overall response within the first treatment cycle was assessed according to International Working Group – Non-Hodgkin Lymphoma criteria (IWG-NHL criteria [Cheson et al, 1999]) by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement), and bone marrow biopsy (to assess bone marrow infiltration). ORR was the percentage of participants with a best overall response of complete response (CR), unconfirmed complete response (CRu) or partial response (PR). Participants that do not meet the criteria for response were considered non-responders.

CR was defined as no evidence of disease.

CRu showed nodes in the original sum of the products (SPD) regressed by >75% and/or indeterminate bone marrow results.

PR was a  $\geq 50\%$  decrease in SPD of the six largest dominant nodes;  $\geq 50\%$  decrease in liver and spleen nodes, and no increase in size of other nodes nor any new sites of disease.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| End point values                  | ABP 798            | Rituximab          |  |  |
|-----------------------------------|--------------------|--------------------|--|--|
| Subject group type                | Reporting group    | Reporting group    |  |  |
| Number of subjects analysed       | 123 <sup>[3]</sup> | 124 <sup>[4]</sup> |  |  |
| Units: percentage of participants |                    |                    |  |  |
| number (not applicable)           | 59.3               | 58.1               |  |  |

Notes:

[3] - The modified full analysis set (mFAS) includes subjects with evidence of disease at baseline

[4] - mFAS

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                                      | ORR at Week 12 90% CI |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Statistical analysis description:<br>The 2-sided 90% confidence limits of the risk difference (RD) of ORR at week 12 used a generalized linear model adjusted for the stratification factors (geographic region and age group). |                       |
| Comparison groups                                                                                                                                                                                                               | ABP 798 v Rituximab   |
| Number of subjects included in analysis                                                                                                                                                                                         | 247                   |
| Analysis specification                                                                                                                                                                                                          | Pre-specified         |
| Analysis type                                                                                                                                                                                                                   |                       |
| Parameter estimate                                                                                                                                                                                                              | Risk difference (RD)  |
| Point estimate                                                                                                                                                                                                                  | 0.9                   |
| Confidence interval                                                                                                                                                                                                             |                       |
| level                                                                                                                                                                                                                           | 90 %                  |
| sides                                                                                                                                                                                                                           | 2-sided               |
| lower limit                                                                                                                                                                                                                     | -9.3                  |
| upper limit                                                                                                                                                                                                                     | 11.2                  |

| Statistical analysis title                                                                                                                                                                                                      | ORR Week 12 95% CI   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Statistical analysis description:<br>The 2-sided 95% confidence limits of the risk difference (RD) of ORR at week 12 used a generalized linear model adjusted for the stratification factors (geographic region and age group). |                      |
| Comparison groups                                                                                                                                                                                                               | ABP 798 v Rituximab  |
| Number of subjects included in analysis                                                                                                                                                                                         | 247                  |
| Analysis specification                                                                                                                                                                                                          | Pre-specified        |
| Analysis type                                                                                                                                                                                                                   |                      |
| Parameter estimate                                                                                                                                                                                                              | Risk difference (RD) |
| Point estimate                                                                                                                                                                                                                  | 0.9                  |
| Confidence interval                                                                                                                                                                                                             |                      |
| level                                                                                                                                                                                                                           | 95 %                 |
| sides                                                                                                                                                                                                                           | 2-sided              |
| lower limit                                                                                                                                                                                                                     | -11.3                |
| upper limit                                                                                                                                                                                                                     | 13.2                 |

---

**Secondary: Pharmacokinetic Serum Concentrations by Visit**

---

|                 |                                               |
|-----------------|-----------------------------------------------|
| End point title | Pharmacokinetic Serum Concentrations by Visit |
|-----------------|-----------------------------------------------|

End point description:

Pharmacokinetic serum samples were analyzed by a central lab. Participants with PK concentrations below the lower limit of quantification (LLOQ) were excluded from these analyses.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Weeks 2, 3, 4, 12 and 20

---

| End point values                                    | ABP 798         | Rituximab       |  |  |
|-----------------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                                  | Reporting group | Reporting group |  |  |
| Number of subjects analysed                         | 128             | 126             |  |  |
| Units: microgram/mL                                 |                 |                 |  |  |
| geometric mean (geometric coefficient of variation) |                 |                 |  |  |
| Week 2 (predose) (n=123, 125)                       | 58.66 (± 50.4)  | 58.63 (± 76.9)  |  |  |
| Week 3 (predose) (n=125, 126)                       | 105.39 (± 37.8) | 108.77 (± 59.1) |  |  |
| Week 4 (predose) (n=126, 121)                       | 132.70 (± 42.6) | 140.23 (± 57.9) |  |  |
| Week 12 (predose) (n=121, 124)                      | 21.86 (± 156.1) | 20.55 (± 194.1) |  |  |
| Week 12 (postdose) (n=113, 117)                     | 207.05 (± 58.1) | 209.14 (± 66.8) |  |  |
| Week 20 (predose) (n=118, 122)                      | 13.37 (± 138.7) | 16.45 (± 115.8) |  |  |

---

**Statistical analyses**

---

No statistical analyses for this end point

---

---

**Secondary: Percentage of Participants with Complete Depletion of Clusters of Differentiation 19-Positive (CD19+) Cell Count From Baseline to Day 8**

---

|                 |                                                                                                                                         |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with Complete Depletion of Clusters of Differentiation 19-Positive (CD19+) Cell Count From Baseline to Day 8 |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Complete depletion of CD19+ cell count at any postdose time was defined as CD19+ cell counts < 20 cell/μL (0.02 \* 10<sup>9</sup> cell/L). Participants with missing CD19+ cell count at baseline or participants with CD19+ cell count < 20 cell/μL at baseline were to be excluded from the derivation of complete depletion of CD19+ cell count.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1), Study Day 8

---

| End point values                  | ABP 798         | Rituximab       |  |  |
|-----------------------------------|-----------------|-----------------|--|--|
| Subject group type                | Reporting group | Reporting group |  |  |
| Number of subjects analysed       | 115             | 116             |  |  |
| Units: percentage of participants |                 |                 |  |  |
| number (not applicable)           | 98.3            | 98.3            |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Total Immunoglobulin G (IgG) Results by Visit

|                                                                          |                                               |
|--------------------------------------------------------------------------|-----------------------------------------------|
| End point title                                                          | Total Immunoglobulin G (IgG) Results by Visit |
| End point description:<br>Samples were analyzed by a central lab.        |                                               |
| End point type                                                           | Secondary                                     |
| End point timeframe:<br>Baseline (Day 1), Day 8 (Week 2), Weeks 3, 4, 28 |                                               |

| End point values                     | ABP 798          | Rituximab         |  |  |
|--------------------------------------|------------------|-------------------|--|--|
| Subject group type                   | Reporting group  | Reporting group   |  |  |
| Number of subjects analysed          | 128              | 128               |  |  |
| Units: 10 <sup>9</sup> /L            |                  |                   |  |  |
| arithmetic mean (standard deviation) |                  |                   |  |  |
| Baseline (n=127, 123)                | 9.740 (± 2.5988) | 10.570 (± 2.5970) |  |  |
| Day 8 (Week 2) (n=122, 123)          | 9.790 (± 2.5719) | 10.486 (± 2.4916) |  |  |
| Week 3 (n=122, 123)                  | 9.545 (± 2.5933) | 10.374 (± 2.3214) |  |  |
| Week 4 (n=124, 121)                  | 9.744 (± 2.5805) | 10.196 (± 2.2842) |  |  |
| Week 28 (n=103, 104)                 | 9.846 (± 2.6316) | 10.281 (± 2.3617) |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Total Immunoglobulin M (IgM) Results by Visit

|                 |                                               |
|-----------------|-----------------------------------------------|
| End point title | Total Immunoglobulin M (IgM) Results by Visit |
|-----------------|-----------------------------------------------|

End point description:

Samples were analyzed by a central lab.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline (Day 1), Day 8 (Week 2), Weeks 3, 4, 28

| End point values                     | ABP 798          | Rituximab        |  |  |
|--------------------------------------|------------------|------------------|--|--|
| Subject group type                   | Reporting group  | Reporting group  |  |  |
| Number of subjects analysed          | 128              | 128              |  |  |
| Units: 10 <sup>9</sup> /L            |                  |                  |  |  |
| arithmetic mean (standard deviation) |                  |                  |  |  |
| Baseline (n=127, 123)                | 1.021 (± 1.0072) | 1.247 (± 3.4018) |  |  |
| Day 8 (Week 2) (n=122, 123)          | 1.004 (± 1.0300) | 1.280 (± 3.7292) |  |  |
| Week 3 (n=122, 122)                  | 1.001 (± 1.0564) | 1.370 (± 5.0250) |  |  |
| Week 4 (n=124, 120)                  | 0.985 (± 1.0459) | 1.385 (± 5.3266) |  |  |
| Week 28 (n=103, 104)                 | 0.816 (± 0.8505) | 1.127 (± 3.6752) |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Participants with Treatment-Emergent Adverse Events

|                 |                                                     |
|-----------------|-----------------------------------------------------|
| End point title | Participants with Treatment-Emergent Adverse Events |
|-----------------|-----------------------------------------------------|

End point description:

An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. Each AE was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, where Grade 1 = Mild AE Grade 2 = Moderate AE Grade 3 = Severe AE Grade 4 = Life-threatening or disabling AE Grade 5 = Death related to AE. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard.

IP = investigational product

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 (post treatment) to Week 28

| End point values                         | ABP 798         | Rituximab       |  |  |
|------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                       | Reporting group | Reporting group |  |  |
| Number of subjects analysed              | 128             | 126             |  |  |
| Units: participants                      |                 |                 |  |  |
| Any AE                                   | 107             | 95              |  |  |
| Any grade ≥3 AE                          | 14              | 13              |  |  |
| Any fatal AE                             | 0               | 0               |  |  |
| Any serious AE                           | 5               | 5               |  |  |
| Any AE leading to discontinuation of IP  | 4               | 1               |  |  |
| Any AE leading to dose delay/withheld IP | 9               | 9               |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with Treatment-emergent Adverse Events of Interest (AEOIs)

|                 |                                                                                       |
|-----------------|---------------------------------------------------------------------------------------|
| End point title | Percentage of Participants with Treatment-emergent Adverse Events of Interest (AEOIs) |
|-----------------|---------------------------------------------------------------------------------------|

End point description:

The AEOIs prespecified for this study were infusion reactions including hypersensitivity, cardiac disorders, serious infections, progressive multifocal leukoencephalopathy, hematological reactions, hepatitis B reactivation, opportunistic infections, severe mucocutaneous reactions, tumor lysis syndrome, gastrointestinal perforation, and reversible posterior leukoencephalopathy syndrome. Infusion reactions including hypersensitivity adverse events of interest must have start date the same as, or one day after, an investigational product administration start date.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 (post treatment) to Week 28

| End point values                              | ABP 798         | Rituximab       |  |  |
|-----------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                            | Reporting group | Reporting group |  |  |
| Number of subjects analysed                   | 128             | 126             |  |  |
| Units: percentage of participants             |                 |                 |  |  |
| number (not applicable)                       |                 |                 |  |  |
| Any AEOI                                      | 49.2            | 45.2            |  |  |
| Infusion reactions including hypersensitivity | 43.0            | 42.9            |  |  |
| Hematological reactions                       | 5.5             | 4.8             |  |  |
| Cardiac disorders                             | 2.3             | 1.6             |  |  |
| Serious infections                            | 1.6             | 0               |  |  |
| Severe mucocutaneous reactions                | 0.8             | 0               |  |  |
| Gastrointestinal perforation                  | 0               | 0               |  |  |
| Hepatitis B reactivation                      | 0               | 0               |  |  |
| Opportunistic infection                       | 0               | 0               |  |  |
| Progressive multifocal leukoencephalopathy    | 0               | 0               |  |  |

|                                          |   |   |  |  |
|------------------------------------------|---|---|--|--|
| Reversible posterior leukoencephalopathy | 0 | 0 |  |  |
| Tumor lysis syndrome                     | 0 | 0 |  |  |

## Statistical analyses

|                                                                                                                                                                                                      |                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                    | Risk Difference: Any AEOI |
| Statistical analysis description:<br>Risk difference (ABP 798 – Rituximab) and CIs were estimated by Wald asymptotic confidence limits, or exact confidence limits if $n < 25$ for either treatment. |                           |
| Comparison groups                                                                                                                                                                                    | ABP 798 v Rituximab       |
| Number of subjects included in analysis                                                                                                                                                              | 254                       |
| Analysis specification                                                                                                                                                                               | Pre-specified             |
| Analysis type                                                                                                                                                                                        | other                     |
| Parameter estimate                                                                                                                                                                                   | Risk difference (RD)      |
| Point estimate                                                                                                                                                                                       | 4                         |
| Confidence interval                                                                                                                                                                                  |                           |
| level                                                                                                                                                                                                | 95 %                      |
| sides                                                                                                                                                                                                | 2-sided                   |
| lower limit                                                                                                                                                                                          | -8.3                      |
| upper limit                                                                                                                                                                                          | 16.3                      |

|                                                                                                                                                                                                      |                                     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                    | Risk Difference: Infusion Reactions |
| Statistical analysis description:<br>Risk difference (ABP 798 – Rituximab) and CIs were estimated by Wald asymptotic confidence limits, or exact confidence limits if $n < 25$ for either treatment. |                                     |
| Comparison groups                                                                                                                                                                                    | ABP 798 v Rituximab                 |
| Number of subjects included in analysis                                                                                                                                                              | 254                                 |
| Analysis specification                                                                                                                                                                               | Pre-specified                       |
| Analysis type                                                                                                                                                                                        | other                               |
| Parameter estimate                                                                                                                                                                                   | Risk difference (RD)                |
| Point estimate                                                                                                                                                                                       | 0.1                                 |
| Confidence interval                                                                                                                                                                                  |                                     |
| level                                                                                                                                                                                                | 95 %                                |
| sides                                                                                                                                                                                                | 2-sided                             |
| lower limit                                                                                                                                                                                          | -12.1                               |
| upper limit                                                                                                                                                                                          | 12.3                                |

|                                                                                                                                                                                                      |                                          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                    | Risk Difference: Hematological Reactions |
| Statistical analysis description:<br>Risk difference (ABP 798 – Rituximab) and CIs were estimated by Wald asymptotic confidence limits, or exact confidence limits if $n < 25$ for either treatment. |                                          |
| Comparison groups                                                                                                                                                                                    | ABP 798 v Rituximab                      |

|                                         |                      |
|-----------------------------------------|----------------------|
| Number of subjects included in analysis | 254                  |
| Analysis specification                  | Pre-specified        |
| Analysis type                           | other                |
| Parameter estimate                      | Risk difference (RD) |
| Point estimate                          | 0.7                  |
| Confidence interval                     |                      |
| level                                   | 95 %                 |
| sides                                   | 2-sided              |
| lower limit                             | -11.8                |
| upper limit                             | 13                   |

|                                                                                                                                                                                                      |                                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                    | Risk Difference: Cardiac Disorders |
| Statistical analysis description:<br>Risk difference (ABP 798 – Rituximab) and CIs were estimated by Wald asymptotic confidence limits, or exact confidence limits if $n < 25$ for either treatment. |                                    |
| Comparison groups                                                                                                                                                                                    | ABP 798 v Rituximab                |
| Number of subjects included in analysis                                                                                                                                                              | 254                                |
| Analysis specification                                                                                                                                                                               | Pre-specified                      |
| Analysis type                                                                                                                                                                                        | other                              |
| Parameter estimate                                                                                                                                                                                   | Risk difference (RD)               |
| Point estimate                                                                                                                                                                                       | 0.8                                |
| Confidence interval                                                                                                                                                                                  |                                    |
| level                                                                                                                                                                                                | 95 %                               |
| sides                                                                                                                                                                                                | 2-sided                            |
| lower limit                                                                                                                                                                                          | -11.8                              |
| upper limit                                                                                                                                                                                          | 13.2                               |

|                                                                                                                                                                                                      |                                     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| <b>Statistical analysis title</b>                                                                                                                                                                    | Risk Difference: Serious Infections |
| Statistical analysis description:<br>Risk difference (ABP 798 – Rituximab) and CIs were estimated by Wald asymptotic confidence limits, or exact confidence limits if $n < 25$ for either treatment. |                                     |
| Comparison groups                                                                                                                                                                                    | ABP 798 v Rituximab                 |
| Number of subjects included in analysis                                                                                                                                                              | 254                                 |
| Analysis specification                                                                                                                                                                               | Pre-specified                       |
| Analysis type                                                                                                                                                                                        | other                               |
| Parameter estimate                                                                                                                                                                                   | Risk difference (RD)                |
| Point estimate                                                                                                                                                                                       | 1.6                                 |
| Confidence interval                                                                                                                                                                                  |                                     |
| level                                                                                                                                                                                                | 95 %                                |
| sides                                                                                                                                                                                                | 2-sided                             |
| lower limit                                                                                                                                                                                          | -10.9                               |
| upper limit                                                                                                                                                                                          | 14                                  |

|                                   |                                                 |
|-----------------------------------|-------------------------------------------------|
| <b>Statistical analysis title</b> | Risk Difference: Severe Mucocutaneous Reactions |
|-----------------------------------|-------------------------------------------------|

**Statistical analysis description:**

Risk difference (ABP 798 – Rituximab) and CIs were estimated by Wald asymptotic confidence limits, or exact confidence limits if  $n < 25$  for either treatment.

|                                         |                      |
|-----------------------------------------|----------------------|
| Comparison groups                       | ABP 798 v Rituximab  |
| Number of subjects included in analysis | 254                  |
| Analysis specification                  | Pre-specified        |
| Analysis type                           | other                |
| Parameter estimate                      | Risk difference (RD) |
| Point estimate                          | 0.8                  |
| Confidence interval                     |                      |
| level                                   | 95 %                 |
| sides                                   | 2-sided              |
| lower limit                             | -11.7                |
| upper limit                             | 13.2                 |

**Secondary: Number of Participants Who Developed Anti-drug Antibodies**

|                 |                                                           |
|-----------------|-----------------------------------------------------------|
| End point title | Number of Participants Who Developed Anti-drug Antibodies |
|-----------------|-----------------------------------------------------------|

**End point description:**

Samples were first tested in an electrochemiluminescence (ECL)-based bridging immunoassay to detect antibodies capable of binding to ABP 798/rituximab (Binding Antibody Assay). Samples confirmed to be positive for binding antibodies were subsequently tested in a cell-based assay to determine neutralizing activity against ABP 798/rituximab (Neutralizing Antibody Assay).

Developing antibody incidence was defined as participants with a negative or no binding antibody result at baseline and a positive antibody result at any post-baseline time point.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

**End point timeframe:**

Baseline (Day 1), Weeks 12, 20 and 28

| End point values                            | ABP 798            | Rituximab          |  |  |
|---------------------------------------------|--------------------|--------------------|--|--|
| Subject group type                          | Reporting group    | Reporting group    |  |  |
| Number of subjects analysed                 | 126 <sup>[5]</sup> | 123 <sup>[6]</sup> |  |  |
| Units: participants                         |                    |                    |  |  |
| Binding antibody positive postbaseline      | 3                  | 1                  |  |  |
| Neutralizing antibody positive postbaseline | 1                  | 1                  |  |  |

**Notes:**

[5] - Subjects with a binding antibody negative or no result at baseline and a post baseline result.

[6] - Subjects with a binding antibody negative or no result at baseline and a post baseline result.

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Participants' Progression-Free Survival (PFS) Status Based on the Independent Central Assessment of Disease**

|                 |                                                                                                             |
|-----------------|-------------------------------------------------------------------------------------------------------------|
| End point title | Participants' Progression-Free Survival (PFS) Status Based on the Independent Central Assessment of Disease |
|-----------------|-------------------------------------------------------------------------------------------------------------|

**End point description:**

PFS was based on disease assessments determined by the central, independent, blinded radiologists'

and oncologist's review.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Day 1 up to Week 28  |           |

| End point values                               | ABP 798         | Rituximab       |  |  |
|------------------------------------------------|-----------------|-----------------|--|--|
| Subject group type                             | Reporting group | Reporting group |  |  |
| Number of subjects analysed                    | 128             | 126             |  |  |
| Units: percentage of participants              |                 |                 |  |  |
| number (not applicable)                        |                 |                 |  |  |
| Participants with disease progression or death | 3.1             | 2.4             |  |  |
| Participants alive and progression-free        | 96.9            | 97.6            |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants Who Survived -- Overall Survival (OS)

|                                                                    |                                                                  |
|--------------------------------------------------------------------|------------------------------------------------------------------|
| End point title                                                    | Percentage of Participants Who Survived -- Overall Survival (OS) |
| End point description:                                             |                                                                  |
| Percentage of participants who were alive at the end of the study. |                                                                  |
| End point type                                                     | Secondary                                                        |
| End point timeframe:                                               |                                                                  |
| Day 1 up to Week 28                                                |                                                                  |

| End point values                  | ABP 798         | Rituximab       |  |  |
|-----------------------------------|-----------------|-----------------|--|--|
| Subject group type                | Reporting group | Reporting group |  |  |
| Number of subjects analysed       | 128             | 126             |  |  |
| Units: percentage of participants | 100             | 100             |  |  |

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Day 1 (post treatment) to Week 28

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 21.0 |
|--------------------|------|

### Reporting groups

|                       |         |
|-----------------------|---------|
| Reporting group title | ABP 798 |
|-----------------------|---------|

Reporting group description:

ABP 798 was administered at a dose of 375 mg/m<sup>2</sup> as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.

|                       |           |
|-----------------------|-----------|
| Reporting group title | Rituximab |
|-----------------------|-----------|

Reporting group description:

Rituximab was administered at a dose of 375 mg/m<sup>2</sup> as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.

| Serious adverse events                            | ABP 798         | Rituximab       |  |
|---------------------------------------------------|-----------------|-----------------|--|
| Total subjects affected by serious adverse events |                 |                 |  |
| subjects affected / exposed                       | 5 / 128 (3.91%) | 5 / 126 (3.97%) |  |
| number of deaths (all causes)                     | 0               | 0               |  |
| number of deaths resulting from adverse events    |                 |                 |  |
| Injury, poisoning and procedural complications    |                 |                 |  |
| Hip fracture                                      |                 |                 |  |
| subjects affected / exposed                       | 1 / 128 (0.78%) | 0 / 126 (0.00%) |  |
| occurrences causally related to treatment / all   | 0 / 1           | 0 / 0           |  |
| deaths causally related to treatment / all        | 0 / 0           | 0 / 0           |  |
| Limb traumatic amputation                         |                 |                 |  |
| subjects affected / exposed                       | 1 / 128 (0.78%) | 0 / 126 (0.00%) |  |
| occurrences causally related to treatment / all   | 0 / 1           | 0 / 0           |  |
| deaths causally related to treatment / all        | 0 / 0           | 0 / 0           |  |
| Cardiac disorders                                 |                 |                 |  |
| Coronary artery stenosis                          |                 |                 |  |
| subjects affected / exposed                       | 0 / 128 (0.00%) | 1 / 126 (0.79%) |  |
| occurrences causally related to treatment / all   | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all        | 0 / 0           | 0 / 0           |  |
| Nervous system disorders                          |                 |                 |  |

|                                                      |                 |                 |  |
|------------------------------------------------------|-----------------|-----------------|--|
| Headache                                             |                 |                 |  |
| subjects affected / exposed                          | 0 / 128 (0.00%) | 1 / 126 (0.79%) |  |
| occurrences causally related to treatment / all      | 0 / 0           | 1 / 1           |  |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           |  |
| General disorders and administration site conditions |                 |                 |  |
| Chills                                               |                 |                 |  |
| subjects affected / exposed                          | 0 / 128 (0.00%) | 1 / 126 (0.79%) |  |
| occurrences causally related to treatment / all      | 0 / 0           | 1 / 1           |  |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           |  |
| Pyrexia                                              |                 |                 |  |
| subjects affected / exposed                          | 1 / 128 (0.78%) | 0 / 126 (0.00%) |  |
| occurrences causally related to treatment / all      | 1 / 1           | 0 / 0           |  |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           |  |
| Gastrointestinal disorders                           |                 |                 |  |
| Abdominal pain                                       |                 |                 |  |
| subjects affected / exposed                          | 0 / 128 (0.00%) | 1 / 126 (0.79%) |  |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           |  |
| Colitis ulcerative                                   |                 |                 |  |
| subjects affected / exposed                          | 0 / 128 (0.00%) | 1 / 126 (0.79%) |  |
| occurrences causally related to treatment / all      | 0 / 0           | 1 / 1           |  |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           |  |
| Dysphagia                                            |                 |                 |  |
| subjects affected / exposed                          | 0 / 128 (0.00%) | 1 / 126 (0.79%) |  |
| occurrences causally related to treatment / all      | 0 / 0           | 1 / 1           |  |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           |  |
| Stomatitis                                           |                 |                 |  |
| subjects affected / exposed                          | 1 / 128 (0.78%) | 0 / 126 (0.00%) |  |
| occurrences causally related to treatment / all      | 2 / 2           | 0 / 0           |  |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           |  |
| Reproductive system and breast disorders             |                 |                 |  |
| Erectile dysfunction                                 |                 |                 |  |

|                                                 |                 |                 |  |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed                     | 0 / 128 (0.00%) | 1 / 126 (0.79%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Respiratory, thoracic and mediastinal disorders |                 |                 |  |
| Rhinorrhoea                                     |                 |                 |  |
| subjects affected / exposed                     | 0 / 128 (0.00%) | 1 / 126 (0.79%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Infections and infestations                     |                 |                 |  |
| Lower respiratory tract infection               |                 |                 |  |
| subjects affected / exposed                     | 1 / 128 (0.78%) | 0 / 126 (0.00%) |  |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Septic shock                                    |                 |                 |  |
| subjects affected / exposed                     | 1 / 128 (0.78%) | 0 / 126 (0.00%) |  |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Viral infection                                 |                 |                 |  |
| subjects affected / exposed                     | 1 / 128 (0.78%) | 0 / 126 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | ABP 798           | Rituximab         |  |
|-------------------------------------------------------|-------------------|-------------------|--|
| Total subjects affected by non-serious adverse events |                   |                   |  |
| subjects affected / exposed                           | 59 / 128 (46.09%) | 61 / 126 (48.41%) |  |
| Nervous system disorders                              |                   |                   |  |
| Headache                                              |                   |                   |  |
| subjects affected / exposed                           | 15 / 128 (11.72%) | 12 / 126 (9.52%)  |  |
| occurrences (all)                                     | 18                | 24                |  |
| General disorders and administration site conditions  |                   |                   |  |
| Asthenia                                              |                   |                   |  |

|                                                                                                                          |                         |                         |  |
|--------------------------------------------------------------------------------------------------------------------------|-------------------------|-------------------------|--|
| subjects affected / exposed<br>occurrences (all)                                                                         | 12 / 128 (9.38%)<br>14  | 6 / 126 (4.76%)<br>9    |  |
| Fatigue<br>subjects affected / exposed<br>occurrences (all)                                                              | 13 / 128 (10.16%)<br>20 | 12 / 126 (9.52%)<br>23  |  |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all)                                                              | 8 / 128 (6.25%)<br>9    | 8 / 126 (6.35%)<br>13   |  |
| Gastrointestinal disorders<br>Abdominal pain<br>subjects affected / exposed<br>occurrences (all)                         | 4 / 128 (3.13%)<br>4    | 9 / 126 (7.14%)<br>16   |  |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all)                                                            | 3 / 128 (2.34%)<br>3    | 9 / 126 (7.14%)<br>11   |  |
| Nausea<br>subjects affected / exposed<br>occurrences (all)                                                               | 6 / 128 (4.69%)<br>7    | 14 / 126 (11.11%)<br>22 |  |
| Respiratory, thoracic and mediastinal disorders<br>Throat irritation<br>subjects affected / exposed<br>occurrences (all) | 9 / 128 (7.03%)<br>10   | 8 / 126 (6.35%)<br>12   |  |
| Skin and subcutaneous tissue disorders<br>Pruritus<br>subjects affected / exposed<br>occurrences (all)                   | 6 / 128 (4.69%)<br>6    | 12 / 126 (9.52%)<br>16  |  |
| Rash<br>subjects affected / exposed<br>occurrences (all)                                                                 | 9 / 128 (7.03%)<br>12   | 6 / 126 (4.76%)<br>7    |  |
| Urticaria<br>subjects affected / exposed<br>occurrences (all)                                                            | 7 / 128 (5.47%)<br>7    | 2 / 126 (1.59%)<br>6    |  |
| Infections and infestations<br>Upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all)     | 7 / 128 (5.47%)<br>7    | 1 / 126 (0.79%)<br>1    |  |



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date             | Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 22 December 2015 | modified subject inclusion/exclusion criteria<br>specified CT of the neck (if palpable lymph node > 1.0 cm or if performed at baseline) chest, abdomen, and pelvis at week 12 and week 28<br>added standard 12-lead ECG to the week-28 (EOS) procedures<br>added reference to possible follow-up testing for subjects testing positive for neutralizing antibodies at the final scheduled study visit<br>clarified that disease progression should not be reported as an adverse event, but that symptoms of progression should be reported<br>removed end-of-infusion PK sampling at week 4 and week 20 |
| 07 January 2016  | - corrected sample size power                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 24 June 2016     | - modified subject inclusion criteria<br>- specified that the dose of ABP 798/rituxima would be calculated based on height and weight obtained at baseline, and that the dose would remain the same throughout the study<br>- added stopping criteria for infusion-related reactions<br>- added additional monitoring requirements for infusion-related hypersensitivity reactions<br>- specified that clinical disease assessments should be performed by investigator or sub-investigator                                                                                                              |
| 17 July 2017     | - added details regarding optional additional PK sampling visit<br>- modified subject inclusion/exclusion criteria<br>- specified visits for physical examination and PK sampling procedures<br>- clarified that the end of study (EOS) biopsies for complete response confirmation were required if bone marrow involvement was identified at baseline, and if not obtained then complete response subjects were to be classified as partial responders                                                                                                                                                 |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported